Source comparison
Melanotan-1 for Men Over 40: Clinical Applications vs Research Use
UV-Independent Pigmentation MC1R activation → eumelanin synthesis without UV exposure FDA-approved (Scenesse) for erythropoietic protoporphyria; Phase III data shows pigmentation in 85% of subjects 4–6 weeks to noticeable darkening at research doses; 8–10 week
This comparison does not assign a generated winner or score.
- UV-Independent Pigmentation
- MC1R activation → eumelanin synthesis without UV exposure
- FDA-approved (Scenesse) for erythropoietic protoporphyria; Phase III data shows pigmentation in 85% of subjects
- 4–6 weeks to noticeable darkening at research doses; 8–10 weeks to plateau
- Validated mechanism; age-related receptor decline extends timeline but does not eliminate effect
- Photoprotection (SPF Increase)
- Increased eumelanin density → higher UV absorption before DNA damage
- Randomized controlled trial (NEJM, 2015) showed 2–3× increase in minimal erythema dose
- Requires sustained dosing for 6–8 weeks before measurable SPF increase
- Strongest evidence base; particularly relevant for men with fair skin or high UV exposure
- Appetite Modulation
- Weak MC4R agonism → transient satiety signaling
- Observational data only; no controlled trials in men over 40
- Highly variable; blunted in men with insulin resistance
- Unreliable for metabolic intervention; MC4R density decline limits effect
- Erectile Function (Hypothesized)
- MC4R pathway overlap with nitric oxide signaling
- No clinical trials; mechanism extrapolated from Melanotan-2 data
- Not applicable; Melanotan-1 is a poor MC4R agonist
- Marketing claim without evidence; Melanotan-2 shows this effect, Melanotan-1 does not
- Anti-Inflammatory Effects
- α-MSH analogs reduce pro-inflammatory cytokine release (TNF-α, IL-6)
- Preclinical models only; no human RCTs for systemic inflammation
- Unknown in aged populations
- Plausible but unproven; requires long-term dosing studies